ELDAPOINT LIMITED

Company number 01096344 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Score: D (Poor)

Eldapoint Limited is displaying several symptoms of financial strain, though it remains solvent. The company is experiencing a significant revenue contraction and persistent operating losses, while its cash reserves have dwindled to a critical level. The balance sheet remains positive, but the overall trend indicates a fragile financial condition requiring urgent corrective measures to avoid further deterioration.


Key Vital Signs

Vital Sign Current (2025) Prior Year (2024) Interpretation
Revenue £12,440,226 £15,452,133 19.5% decline – a sharp contraction, mainly in the manufacturing division
Operating Profit/Loss (£1,540,644) (£1,648,809) Persistent loss – though slightly improved, the loss margin widened from -10.7% to -12.4%
Gross Margin 15.6% 15.3% Slight improvement – pricing or cost control may be stabilising
Cash & Cash Equivalents £55,132 £407,185 Severe cash depletion – a drop of 86%, leaving minimal liquidity buffer
Net Assets (Shareholders’ Funds) £6,317,589 £7,750,781 18.5% decrease – retained losses eroding the equity base
Trade Debtor Days 58 days 82 days Significant improvement – better credit control and collection
Trade Creditor Days Not explicitly stated, but creditors fell from £1.9M to £1.6M – Reflects reduced purchasing and possibly tighter supplier terms
Stock Levels Reduced by £815k – Positive – working capital freed, but must balance with service needs
Long-Term Debt Facility with PGIM Capital, subject to EBITDA and liquidity covenants – Key risk – covenant compliance is critical; any breach could trigger acceleration

Working capital pulse: The company has made genuine progress in tightening debtor and stock management, but the cash position remains dangerously low for a business of this size.


Diagnosis

Eldapoint Limited is in a turnaround phase with acute cash-flow anaemia. The financial statements reveal a business that has taken deliberate steps to improve operational efficiency and working capital, yet the core revenue engine (manufacturing) is under severe pressure from post-COVID customer destocking. The depot division’s modest growth provides some offset, but not enough to return the company to profitability.

Balance sheet health is adequate: net assets of £6.3 million and total assets of £18.8 million provide a cushion. However, the rapid depletion of cash (from £407k to £55k) is a red flag. The company relies heavily on invoice discounting and a long-term debt facility with financial covenants. While the auditor raised no material uncertainty on going concern, the margin for error is thin.

The strategic investments in group management roles (credit control, procurement, technical manager) are positive signs of self-correction, but their full effect on profitability has yet to materialise. The increase in gross margin suggests some underlying pricing or mix improvement, but the operating loss remains stubbornly high.

Principal risks: - Continued revenue decline in manufacturing - Covenant breach under the PGIM facility if EBITDA does not recover - Insufficient cash to absorb unexpected shocks or fund growth without further borrowing


Recommendations

  1. Accelerate cash generation – Despite improved debtor days, the cash balance is critical. Consider tighter credit terms, early payment discounts, or selective factoring to boost liquidity. Review all non-essential capital expenditure until cash stabilises.

  2. Strengthen covenant headroom – Engage proactively with PGIM Capital. Provide regular forecasts and, if necessary, seek covenant relaxation or a waiver before any breach occurs. The appointment of a Chief Commercial Officer post-year-end may help drive revenue, but near-term covenant compliance is paramount.

  3. Restore manufacturing profitability – The division’s revenue drop is the primary cause of losses. Conduct a detailed review of product-line profitability, capacity utilisation, and pricing. Consider rationalising low-margin or loss-making lines to stem cash outflows.

  4. Build a cash reserve target – Set a minimum cash buffer (e.g., £300k–£500k) and treat it as a key performance indicator. The current £55k is insufficient for a company with £12.4m turnover and exposes the business to payment shocks.

  5. Monitor group-level leverage – As a subsidiary of Eldapoint Holdings Ltd, ensure that intra-group transactions and dividend policies do not further strain the company’s liquidity. The parent’s support may be needed if losses persist.

  6. Continue working capital discipline – The improvements in debtor and stock management are commendable. Maintain these practices and extend them to creditor management where possible, while preserving supplier relationships.


Eldapoint Limited is in a financially fragile state, with a sharp drop in revenue and persistent operating losses that have eroded net assets and left cash reserves critically low. The company has taken positive steps to improve working capital and invest in management, but it remains heavily dependent on debt facilities and covenant compliance. Without a swift recovery in manufacturing revenues or a significant reduction in costs, the business faces a high risk of further financial deterioration.

Perspective: Financial Health Diagnostician · Model: deepseek/deepseek-v4-flash · Generated 13 November 2026